11 June 2020 

South Korea-based Daewoong Pharmaceutical has found that its anti-parasitic drug niclosamide removed SARS-CoV-2, the novel coronavirus that causes Covid-19, from lungs in animal models. The company added that the drug completely cleared the infection in ferrets’ lung tissues and inhibited inflammation, according to Reuters.

China-based Sinovac Biotech has joined the list of the Philippines Government’s potential collaborators for Covid-19 vaccine development and clinical trials. Last month, Sinovac Biotech announced that the company is in talks to perform late-stage trials of its Covid-19 vaccine candidate worldwide.

GlaxoSmithKline (GSK) has commenced a clinical trial of an experimental rheumatoid arthritis drug, called otilimab, to treat patients with pneumonia caused by Covid-19 in the US. The company intends to expand the study to include patients in the UK, Italy, Spain, South America and Africa, reported Reuters.

Twist Bioscience has partnered with Serimmune to identify and assess anti-SARS-CoV-2 therapeutic antibody candidates. The partners will use Serimmune’s Serum Epitope Repertoire Analysis (SERA) platform to analyse existing Twist antibody candidates with high affinity to bind to SARS-CoV-2’s spike protein or the human ACE2 cellular receptor.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.